Allergy/Asthma

AR101, an immunotherapy treatment option for peanut allergy created by Aimmune Therapeutics Inc. is effective in increasing tolerance to peanut protein in children aged between 4 and 17 years, with 67.2% of children tolerating up to 600 mg of peanut protein, according to phase 3 study results released by the company.

Infants of mothers who consume peanuts while breast-feeding and directly introduce their child to the food by 12 months of age are less likely to be sensitized to peanuts, according to a study published in The Journal of Allergy and Clinical Immunology.

Children with asthma experienced fewer asthma attacks between 2001 and 2016, according to a recent Vital Signs report from the CDC.

In a new position statement, the American College of Allergy, Asthma and Immunology advocates for physicians to incorporate meaningful and sustained use of telemedicine in the care of patients with allergies.

Children who have a chronic physical illness such as asthma, diabetes, epilepsy, food allergy or juvenile arthritis are likely to experience a mental disorder, with 58% of children experiencing both physical and psychological conditions at time of diagnosis.

Children delivered by cesarean were at higher risk for obesity and asthma, but cesarean deliveries were linked to a lower risk of pelvic prolapse and urinary incontinence among mothers, according to a systematic review and meta-analysis recently published in PLOS Medicine.

The implementation of an urban school-based telemedicine program that promotes preventive care for children with persistent asthma is able to increase the number of days without symptoms and decrease the likelihood of hospitalization and ED visits.

According to the American College of Allergy, Asthma and Immunology, allergies are the sixth leading cause of chronic illness in the U.S, affecting more than 50 million people annually.

The FDA has approved changing the boxed labeling on inhaled corticosteroid/long-acting beta2 antagonist combination medications manufactured by GlaxoSmithKline upon review of four randomized controlled safety trials in children aged 4 to 11 years, as well as adolescents and adults.

Children between the ages of 2 and 5 years with overweight or obesity experience asthma symptoms and exacerbations more frequently than children of the same age with normal weight; however, inhaled corticosteroids can reduce the annual symptom days and exacerbations experienced by this demographic.